Zyprexa news | Breaking Zyprexa news | Zyprexa

TODAY ON PHARMALIVE.COM

... "There is no easy cure for Eli Lilly's woes," said Kadens.

"It's critical that the company stop the bleeding with its mature drugs and flex its muscles on its newer ones, although it will be tougher to reverse slides in specialty/diagnosis markets that are declining." "The working assumption that we have about the value of our proprietary methodology is that better insights can be obtained when analyzing drugs competing across multiple indications and/or competing against drugs having multiple indications," said Kadens.

Many of Eli Lilly's drugs are prescribed for more than one disease indication.

For example, Eli Lilly's antipsychotic drug "We can provide accurate estimates of In 2004, U.S.

sales for Eli Lilly.

Among psychiatrists, Read more...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news

Medicine   Health and Fitness